Antigen Discovery Inc.'s (ADi, formerly ImmPORT Therapeutics Inc. ) technology platform alleviates the major bottleneck that currently limits the transformation of genomic information into next generation medical advancements.
ADi’s high throughput technology surveys mammalian immune responses in a fast and comprehensive manner. The methods rapidly identify novel biomarkers, vaccine targets, and therapeutic protein candidates from infectious organisms, auto-immune disease states, and cancers.
ADi’s powerful technology is also ideal for both preclinical and human clinical trial applications such as enrollment screening and endpoint assessment.
The primary advantages are:
Speed: Application of ADi’s technology requires only DNA sequence and genomic DNA. Final screening results of the entire target proteome can be completed within weeks. ADi’s technology is the fastest path to build a product candidate pipeline.
Proven success rate: To date >95% of all viral and bacterial predicted open reading frames have been successfully expressed and printed onto high density proteome chips. Given this comprehensive coverage, no pre-screening or selection of sequences is required.
Clinical sample volume size: ADi’s proteomic assays are typically conducted with only 1-10 microliters of blood or sera.